Resistance to Anticancer Antibodies: From Mechanisms to Solutions
作者： Lina Reslan , Charles Dumontet
DOI: 10.1007/978-1-4614-7654-2_1
关键词:
摘要: Therapeutic monoclonal antibodies exert their antitumor effect through a variety of mechanisms, including apoptotic induction, extracellular mechanisms and the involvement innate possibly adaptative immune systems. Due to this complexity there are still few data regarding resistance antibody therapy. In review, we discuss available for three best described antibodies, rituximab, trastuzumab cetuximab. A approaches strategies has been suggested or currently being tested circumvent these antibodies.
springer.com
sci-hub.st 参考文章(140)
Josée Golay, Luisella Zaffaroni, Thomas Vaccari, Manuela Lazzari, Gian-Maria Borleri, Sergio Bernasconi, Francesco Tedesco, Alessandro Rambaldi, Martino Introna, Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood. ,vol. 95, pp. 3900- 3908 ,(2000) , 10.1182/BLOOD.V95.12.3900
Abraham Klepfish, Lugassy Gilles, Kotsianidis Ioannis, Rachmilewitz Eliezer, Schattner Ami, Enhancing the Action of Rituximab in Chronic Lymphocytic Leukemia by Adding Fresh Frozen Plasma Annals of the New York Academy of Sciences. ,vol. 1173, pp. 865- 873 ,(2009) , 10.1111/J.1749-6632.2009.04803.X
Mario I. Vega, Ali R. Jazirehi, Sara Huerta-Yepez, Benjamin Bonavida, Rituximab-Induced Inhibition of YY1 and Bcl-xL Expression in Ramos Non-Hodgkin’s Lymphoma Cell Line via Inhibition of NF-κB Activity: Role of YY1 and Bcl-xL in Fas Resistance and Chemoresistance, Respectively Journal of Immunology. ,vol. 175, pp. 2174- 2183 ,(2005) , 10.4049/JIMMUNOL.175.4.2174
S. Kopetz, J. Desai, E. Chan, J. R. Hecht, P. J. O'Dwyer, R. J. Lee, K. B. Nolop, L. Saltz, PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. Journal of Clinical Oncology. ,vol. 28, pp. 3534- 3534 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.3534
Elizabeth Repasky, Ezogelin Oflazoglu, Myron S Czuczman, Venkata Jupudy, Julie Ostberg, Francisco J Hernandez-Ilizaliturri, Amy Huberman, Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clinical Cancer Research. ,vol. 9, pp. 5866- 5873 ,(2003)
Paul V. Beum, Adam D. Kennedy, Michael E. Williams, Margaret A. Lindorfer, Ronald P. Taylor, The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes Journal of Immunology. ,vol. 176, pp. 2600- 2609 ,(2006) , 10.4049/JIMMUNOL.176.4.2600
Alja J. Stel, Bram ten Cate, Susan Jacobs, Jan Willem Kok, Diana C. J. Spierings, Monica Dondorff, Wijnand Helfrich, Hanneke C. Kluin-Nelemans, Lou F. M. H. de Leij, Sebo Withoff, Bart Jan Kroesen, Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis Journal of Immunology. ,vol. 178, pp. 2287- 2295 ,(2007) , 10.4049/JIMMUNOL.178.4.2287
Barbara Pro, Brian Leber, Mitchell Smith, Luis Fayad, Jorge Romaguera, Fredrick Hagemeister, Alma Rodriguez, Peter McLaughlin, Felipe Samaniego, James Zwiebel, Adriana Lopez, Larry Kwak, Anas Younes, Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. British Journal of Haematology. ,vol. 143, pp. 355- 360 ,(2008) , 10.1111/J.1365-2141.2008.07353.X
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
Wen-Kai Weng, Ronald Levy, Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma Journal of Clinical Oncology. ,vol. 21, pp. 3940- 3947 ,(2003) , 10.1200/JCO.2003.05.013